Market Outlook

By 2035, the U.S. Handheld Point-of-Care Testing Devices Market is expected to reach approximately USD 15.77 billion, expanding at a CAGR of 9.30% during the forecast period 2026–2035. The market is estimated at USD 6.48 billion in 2025, following historical expansion from approximately USD 5.02 billion in 2021, USD 5.26 billion in 2022, USD 5.64 billion in 2023, and USD 6.02 billion in 2024. Values in this report are expressed in USD billions.

For market-sizing purposes, the scope includes handheld and highly portable near-patient testing analyzers, meters and instrumented readers together with proprietary cartridges, strips, cassettes and assay consumables used specifically with these platforms. Major categories include glucose and ketone meters, handheld blood gas and electrolyte analyzers, coagulation and INR meters, cardiac biomarker systems, hemoglobin and hematocrit devices, portable infectious-disease readers, multiparameter clinical chemistry systems and other connected point-of-care diagnostic platforms. Central laboratory analyzers, continuous glucose monitoring wearables and non-instrumented disposable rapid tests are excluded where they do not require a dedicated handheld or portable reader.

The U.S. market is moving from single-parameter bedside testing toward a connected decentralized diagnostics ecosystem capable of delivering clinically actionable information before the patient leaves the emergency department, examination room, ambulance, operating suite or retail clinic. The economic value of handheld testing is therefore increasingly linked to time-to-decision rather than test cost alone. A device that shortens diagnostic turnaround, accelerates therapeutic intervention, prevents an unnecessary admission, supports same-visit prescribing or eliminates sample transport can create considerably more value for a health system than its direct acquisition cost suggests.

The addressable testing infrastructure is substantial. The United States has more than 6,000 hospitals, more than 900,000 staffed hospital beds and over 35 million annual hospital admissions. Emergency departments handle well above 150 million visits in a year, while the urgent care industry now includes more than 15,000 centers. Decentralized diagnostics also operate across physician offices, pharmacies, community clinics, nursing facilities, home healthcare organizations, dialysis centers, ambulatory surgery centers, emergency medical services and employer health locations.

Chronic disease reinforces this recurring demand. Tens of millions of Americans live with diabetes and chronic kidney disease, while cardiovascular disease, anticoagulation management, respiratory infections and acute metabolic disorders generate large recurring volumes of glucose, electrolyte, lactate, blood gas, INR, cardiac biomarker and infectious-disease tests. The installed base is further supported by the unusually broad U.S. CLIA-waived testing network, which enables appropriately categorized tests to move beyond traditional hospital laboratories into decentralized care settings.

The strongest growth through 2035 will come from multiparameter cartridge systems, high-sensitivity cardiac testing, digital connectivity, miniaturized molecular diagnostics, automated quality-control functionality and CLIA-waived platforms capable of expanding into physician offices, urgent care and community-based testing. Manufacturers able to combine analytical performance with low operator burden, compact workflow, cybersecurity, connectivity and predictable consumable economics will gain the greatest procurement advantage.

 

Introduction

According to the U.S. Handheld Point-of-Care Testing Devices Market Report, decentralized diagnostics has become a fundamental component of U.S. clinical workflow rather than a niche substitute for central laboratory testing. The core value proposition is the ability to perform a clinically meaningful test near the patient, obtain a result within minutes and use that result during the same episode of care. This has particular importance in emergency medicine, intensive care, diabetes management, anticoagulation, surgery, urgent care, primary care, infectious-disease management, ambulatory medicine and rural healthcare.

The market has evolved substantially from the traditional model dominated by portable blood glucose meters. Contemporary handheld point-of-care devices can measure combinations of blood gases, electrolytes, chemistries, lactate, hematocrit, coagulation parameters, cardiac biomarkers, hemoglobin and infectious-disease markers from small sample volumes. Advances in microfluidics, biosensors, immunoassay chemistry, optical detection and miniaturized molecular systems are steadily increasing the number of assays that can be moved closer to the patient.

The scale of U.S. laboratory decentralization creates an unusually attractive commercial environment. Hundreds of thousands of testing sites operate under CLIA, with certificate-of-waiver locations accounting for the majority of the registered non-exempt laboratory base. Physician-office laboratories alone represent a large potential installed base. The implication for manufacturers is important: product design must address not only analytical sensitivity and specificity but also the practical needs of nurses, medical assistants, pharmacists, emergency personnel and other operators who may not be trained laboratory technologists.

Handheld POC testing also aligns with one of the most important structural changes in U.S. healthcare: the movement of appropriate diagnostic activity away from centralized hospital infrastructure. Urgent care centers, retail clinics, physician offices and outpatient facilities increasingly need enough diagnostic capability to make immediate treatment decisions without reproducing the complexity of a hospital laboratory. As more care migrates to lower-cost sites, the commercial value of a compact CLIA-waived platform with multiple reimbursable assays increases.

Hospital procurement is simultaneously becoming more sophisticated. Large integrated delivery networks increasingly assess point-of-care systems at the enterprise level, examining instrument standardization, cartridge utilization, nursing workflow, interface costs, cybersecurity requirements, middleware compatibility, training burden, quality-control processes and waste. Manufacturers that can standardize one platform across emergency departments, intensive care units, operating rooms, ambulatory clinics and affiliated physician practices may achieve stronger account penetration than vendors supplying isolated single-test devices.

From 2026 to 2035, the strategic direction of the market will therefore shift from portable testing devices to distributed diagnostic platforms. The distinction is significant. Winning systems will increasingly combine testing hardware, proprietary consumables, quality management, operator identification, cloud or middleware connectivity, electronic medical record integration, remote fleet management and expanding assay menus.

 

Key Market Drivers: What’s Fueling the U.S. Handheld Point-of-Care Testing Devices Market Boom?

The first major growth driver is the size of the U.S. chronic disease testing burden. Diabetes alone affects tens of millions of Americans and generates continuous demand for glucose, ketone and glycated-hemoglobin assessment across hospitals, physician offices and home-care environments. Prediabetes extends the addressable screening population substantially further. Chronic kidney disease affects more than one in seven U.S. adults, supporting demand for creatinine, electrolyte and metabolic assessment. These conditions are highly relevant to POC manufacturers because they require repeated rather than one-time diagnostic interaction.

A second driver is the scale of acute-care throughput. U.S. emergency departments manage more than 150 million visits in a year, and rapid diagnostics can materially alter emergency workflow. Blood gases, electrolytes, lactate, glucose, hemoglobin and cardiac biomarkers are frequently required when physicians are evaluating chest pain, respiratory distress, shock, sepsis, diabetic emergencies, trauma, bleeding or acute renal dysfunction. Delivering results at bedside can reduce transport and laboratory processing delays while accelerating decisions involving imaging, treatment, admission, transfer or discharge.

A third driver is the rapid expansion of urgent care and decentralized ambulatory medicine. The U.S. urgent care network has grown to more than 15,000 locations and serves well over 100 million patient encounters annually. These facilities need diagnostics that are fast, easy to operate and economical at moderate throughput. Influenza, RSV, COVID-19, Group A streptococcus, glucose, urinalysis and selected chemistry or hematology testing can improve same-visit diagnosis and prescribing. Increasing assay breadth therefore expands the clinical usefulness of each installed reader.

A fourth driver is the scale of the CLIA-waived testing ecosystem. The United States has more than 300,000 registered laboratory locations, with well over 200,000 operating under certificates of waiver. This dramatically expands the number of locations at which appropriately categorized testing can be performed. For manufacturers, obtaining a waiver can materially alter a product’s commercial addressable market by opening physician offices, community clinics, urgent care centers, pharmacies and other decentralized settings in which moderate-complexity testing would create staffing and compliance barriers.

A fifth driver is hospital pressure to improve turnaround time and staff productivity. Central laboratories remain essential for high-throughput and complex testing, but transporting specimens through a hospital can add time at precisely the point where clinicians need immediate information. Handheld testing is particularly attractive where a few minutes can influence resuscitation, anticoagulation reversal, respiratory management, surgical decisions or emergency disposition. The strongest business cases therefore involve workflow redesign rather than simple replacement of central-laboratory tests.

A sixth driver is the expansion of outpatient and home-centered healthcare. Health systems and payers increasingly seek to manage appropriate patients outside expensive inpatient settings. Handheld diagnostic platforms can support home health visits, anticoagulation monitoring, diabetes management, chronic disease assessment and post-discharge care. The opportunity is strongest for devices that require minimal sample preparation, provide automated interpretation and securely transmit results to clinicians.

A seventh driver is the growing importance of diagnostic stewardship and same-visit clinical decision-making. Point-of-care testing is commercially attractive when a result immediately changes therapy. Respiratory testing can influence antiviral treatment and antibiotic stewardship. INR testing can guide anticoagulation management. Troponin testing can support cardiac evaluation. Lactate can assist assessment of critically ill patients. The value of these technologies is highest when a rapid test replaces uncertainty and compresses the clinical pathway.

Finally, U.S. hospitals are increasingly treating connectivity as a procurement requirement rather than an optional feature. A fleet of hundreds or thousands of handheld analyzers can create substantial compliance risk if patient identification, quality-control records, operator credentials and results are managed manually. Devices capable of automatically transmitting structured data into laboratory information systems and electronic health records therefore have a growing advantage, particularly in large integrated delivery networks.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. handheld POC testing market is increasingly centered on multiparameter capability. Earlier generations of point-of-care systems frequently measured one analyte or one narrow panel. Newer cartridge-based platforms are moving toward broader combinations of gases, electrolytes, metabolites, hematocrit and biomarkers. This improves device utilization and gives hospitals a stronger economic reason to standardize around fewer platforms.

High-sensitivity cardiac testing represents another important innovation frontier. Cardiac troponin has major implications for emergency-department workflow because faster and more analytically capable testing can support rapid chest-pain pathways. Continued regulatory progress for high-sensitivity troponin assays on portable platforms could materially expand the role of handheld testing in emergency medicine, particularly when results can be incorporated into standardized rule-out and rule-in algorithms.

Microfluidics is also changing platform economics. Miniaturized fluid channels can perform sample separation, reagent interaction and analytical measurement using small quantities of blood. This helps manufacturers reduce sample-volume requirements while placing increasingly sophisticated chemistry inside disposable cartridges. Over time, greater cartridge integration should reduce manual handling and enable testing by a wider group of non-laboratory operators.

Molecular diagnostics is moving progressively closer to the patient. Traditional PCR systems required centralized laboratories, trained technologists and relatively complex preparation. Compact nucleic-acid amplification systems now enable selected infectious-disease testing in near-patient environments. The next competitive phase will focus on shortening time to result, reducing hands-on steps and lowering instrument and cartridge cost sufficiently to make molecular testing economical outside major hospitals.

Connectivity represents an equally important innovation cycle. Modern handheld testing systems are increasingly expected to support wireless transmission, barcode scanning, operator locking, patient identification, quality-control monitoring, fleet administration and middleware integration. These capabilities may not directly improve analytical sensitivity, but they can materially improve hospital economics by reducing transcription error, compliance burden and administrative labor.

Manufacturers are also investing in assay-menu expansion without hardware replacement. This is commercially powerful because each newly cleared cartridge or assay increases the revenue potential of an existing installed instrument base. Hospitals likewise benefit because adding a test to an existing validated device may be operationally easier than introducing an entirely new analyzer. Platform companies with credible pipelines across chemistry, immunoassay and molecular testing therefore have greater long-term value than vendors dependent on a single assay.

Artificial intelligence will have a more selective role than in imaging markets, but algorithmic support will increasingly appear around test interpretation, quality-control detection, device maintenance, result triage and population-level data management. The greatest value will likely arise not from replacing clinicians but from identifying unusual patterns, preventing operator errors and improving visibility across large distributed fleets.

The final innovation priority is simplification. Point-of-care testing frequently fails operationally when systems are analytically strong but too complex for decentralized use. Cartridge loading, specimen collection, calibration, cleaning, quality control, operator training and troubleshooting therefore matter greatly. The next generation of successful products will increasingly behave like controlled clinical appliances: minimal steps, automated checks, unambiguous results and limited opportunities for operator variation.

 

Segmentation Insights

The U.S. Handheld Point-of-Care Testing Devices Market is segmented on the basis of product type, clinical test category, technology, end user and geography.

 

By Product Type

Handheld Blood Glucose and Metabolic Meters

Handheld glucose meters represent the largest installed product category and account for an estimated USD 1.95 billion of market value in 2025 when dedicated meters and associated proprietary professional and self-testing consumables within the report scope are considered. The category benefits from the enormous U.S. diabetes population and frequent testing requirements in hospitals, physician offices and home-care environments.

The competitive direction is shifting away from standalone measurement toward connected diabetes ecosystems. Hospital-grade systems increasingly incorporate patient identification, operator management and automatic result transmission, while home-use meters are integrating with mobile applications and care-management platforms. Conventional self-monitoring faces competition from continuous glucose monitoring, but blood glucose meters remain essential for confirmation, acute-care use, insulin management and populations that do not use CGM.

Handheld Blood Gas, Electrolyte and Lactate Analyzers

This segment is estimated at approximately USD 1.10 billion in 2025 and represents one of the most strategically important categories in acute care. Handheld cartridge systems can deliver gases, sodium, potassium, ionized calcium, glucose, hematocrit, lactate and other parameters at or near bedside.

Demand is concentrated in emergency medicine, intensive care, surgery, critical transport and respiratory management. The market benefits from high clinical urgency because central-laboratory turnaround can be operationally unacceptable during resuscitation or rapidly changing physiological conditions.

Handheld Coagulation and INR Devices

The coagulation category represents approximately USD 0.76 billion in 2025 within the defined scope. Portable prothrombin-time and INR testing is used across anticoagulation clinics, physician offices, hospitals and home-monitoring programs.

Growth is moderated by the movement of some patients from warfarin to direct oral anticoagulants, which require less routine monitoring. However, warfarin remains important in selected populations, including certain patients with mechanical heart valves and other clinical circumstances. Handheld coagulation testing also remains valuable in procedural and acute-care environments.

Cardiac Biomarker and Critical-Care Handheld Systems

Cardiac biomarker and critical-care handheld systems represent an estimated USD 0.65 billion in 2025. Troponin is the most strategically important growth opportunity because of the size of the U.S. chest-pain population and the operational importance of emergency-department disposition.

The addition of high-sensitivity cardiac assays to portable systems could increase both testing frequency and instrument value. Hospitals considering these platforms will evaluate analytical performance in conjunction with clinical pathways, throughput, connectivity and cost per reportable result.

Portable Infectious-Disease Readers and Molecular POC Systems

Instrumented infectious-disease POC testing is estimated at approximately USD 0.85 billion in 2025. The segment includes portable antigen and fluorescence readers and compact near-patient molecular systems used for respiratory pathogens, streptococcal disease and selected other infectious conditions.

COVID-19 created an extraordinary acceleration in decentralized testing infrastructure, but the post-pandemic commercial opportunity is becoming more diversified. Influenza, RSV, Group A strep, sexually transmitted infections, hepatitis and other pathogens provide recurring demand. Multiplex respiratory testing is particularly valuable when symptoms overlap and treatment choices differ.

Handheld Hemoglobin and Hematology Devices

Handheld hemoglobin and hematocrit devices account for approximately USD 0.47 billion in 2025. Important use environments include emergency departments, blood donation, maternal health, surgery, primary care and anemia screening.

These platforms benefit from low sample requirements and rapid results. Future differentiation will increasingly depend on quality controls, connectivity and the ability to expand beyond a single hematology parameter.

Other Multiparameter Chemistry and Specialty POC Devices

Other handheld and near-handheld chemistry, lipid, renal-function, ketone, urinalysis and specialty platforms collectively account for approximately USD 0.70 billion in 2025. Although fragmented, this segment has attractive growth potential because decentralized chronic-disease management increasingly requires multiple analytes rather than isolated glucose testing.

 

By Clinical Test Category

Glucose, HbA1c and Ketone Testing

Diabetes-related testing remains the largest clinical category because of disease prevalence and recurring utilization. More than 38 million Americans live with diabetes, while a substantially larger population has prediabetes. Glucose testing dominates volume, while HbA1c supports longer-term disease assessment and ketone testing becomes important in acute metabolic deterioration.

The strategic opportunity is migrating from commodity glucose measurement toward connected disease-management platforms that combine reliable testing with data integration and clinical oversight.

Blood Gas, Electrolyte and Lactate Testing

Blood gas, electrolyte and lactate testing is one of the highest-value hospital POC categories because it directly supports emergency and critical-care decisions. These tests are used in respiratory failure, shock, sepsis, trauma, surgery and complex metabolic conditions.

The segment benefits from a strong economic argument: a rapid result can change treatment within minutes. This supports continued hospital spending even when health systems impose broader capital constraints.

Coagulation Testing

Coagulation testing includes INR, PT and selected activated clotting applications. Demand is driven by anticoagulation management, procedural care and emergency assessment. The segment increasingly competes on ease of specimen collection, quality assurance and remote transmission rather than analytical capability alone.

Home INR monitoring provides a distinct recurring-consumable model in which patient convenience and clinician oversight can coexist through connected platforms.

Cardiac Biomarker Testing

Cardiac biomarker testing is expected to be one of the faster-growing categories through 2035. High-sensitivity troponin is central to modern evaluation of suspected myocardial infarction, and faster near-patient results can help emergency departments improve chest-pain throughput.

The commercial ceiling will depend heavily on FDA-cleared assay availability, clinical guideline integration and whether hospital laboratories are comfortable decentralizing testing while maintaining analytical governance.

Infectious-Disease Testing

Respiratory and infectious-disease testing has shifted from pandemic-driven emergency deployment toward a broader permanent role in outpatient medicine. Influenza, RSV, COVID-19 and streptococcal testing remain major use cases, while molecular platforms are opening additional opportunities.

Clinical value is strongest when diagnosis enables immediate treatment or reduces unnecessary antimicrobial use. This makes urgent care, pediatric practices and primary care particularly important settings.

Hemoglobin, Hematocrit and Anemia Testing

Hemoglobin and hematocrit testing supports blood donation, surgery, emergency evaluation, maternal health and chronic anemia management. Aging populations and chronic kidney disease sustain underlying demand.

Handheld testing can be particularly useful where phlebotomy infrastructure is limited or where immediate confirmation is needed before treatment or procedure decisions.

Lipid, Renal and Other Chemistry Testing

Portable lipid, creatinine and general chemistry measurements represent a smaller but expanding category. Chronic kidney disease affects tens of millions of U.S. adults, creating opportunities for renal-function assessment closer to the patient.

Expansion will depend on whether device manufacturers can place multiple economically meaningful assays on common platforms rather than requiring separate instruments for each chemistry.

 

By Technology

Electrochemical Biosensor Technology

Electrochemical biosensors represent the largest technology category, accounting for roughly 42% of the 2025 market. The technology is widely used across glucose, blood gases, electrolytes, lactate and selected coagulation or chemistry applications.

Its position is supported by rapid measurement, small sample volume and mature manufacturing economics. Future differentiation will center on calibration stability, sensor accuracy and multiplexing rather than the basic sensing principle.

Optical and Photometric Technology

Optical and photometric systems are widely used for hemoglobin, chemistry and selected coagulation applications. They offer mature analytical performance and can be integrated into compact handheld formats.

Manufacturers are improving light sources, detector sensitivity and cartridge design to reduce instrument size while maintaining analytical reliability.

Immunoassay and Fluorescence Reader Technology

Instrumented immunoassay systems are increasingly important in infectious disease, cardiac biomarkers and other protein-based diagnostics. Fluorescence readers improve objectivity compared with visually interpreted rapid tests and can automatically capture results into digital systems.

This category should benefit from expanding multiplex respiratory assays and higher-sensitivity biomarker testing.

Molecular and Nucleic-Acid Amplification Technology

Molecular technology is expected to record the fastest growth, potentially exceeding a 13% CAGR through 2035 from a comparatively small base. Its advantage is the ability to bring laboratory-grade pathogen detection closer to the patient.

The central commercial challenge remains cost and operational simplicity. Platforms capable of combining minimal sample preparation, sub-hour results and CLIA-waived workflow could materially expand molecular diagnostics outside hospital laboratories.

Microfluidic and Lab-on-Chip Technology

Microfluidic architecture underpins an increasing number of advanced cartridge platforms. It allows sample movement, reagent storage, reaction control and multiple measurements to be integrated into a small disposable device.

Microfluidics will be an enabling technology behind broader multiplexing, smaller sample requirements and increasingly automated operation.

Digitally Connected Multiparameter Platforms

Connectivity is becoming a technology segment in its own right because buyers increasingly differentiate devices according to data-management capability. Bluetooth, Wi-Fi, barcode identification, cloud connectivity and middleware interfaces enable large POC fleets to operate within laboratory governance.

Over the forecast period, disconnected devices will face increasing procurement disadvantage in large hospitals and health systems.

 

By End User

Hospitals and Health Systems

Hospitals and health systems represent the largest end-user segment and account for approximately 45% of market value in 2025. Emergency departments, critical-care units, operating rooms, labor and delivery, dialysis programs and inpatient nursing floors collectively generate high testing volumes.

Large systems increasingly procure POC devices through centralized value-analysis and laboratory committees. Connectivity, standardized consumables, infection control, service coverage and enterprise pricing can determine vendor selection as much as device accuracy.

Physician Offices and Primary Care Practices

Physician offices are a substantial decentralized testing opportunity because tens of thousands of locations operate CLIA-waived testing programs. Diabetes, coagulation, hemoglobin, respiratory infection and other rapid tests can support same-visit treatment decisions.

The winning product profile differs from that of a tertiary hospital. Physician practices favor low maintenance, simple QC, small footprint and predictable reimbursement.

Urgent Care, Retail Clinics and Pharmacies

Urgent care represents one of the most attractive growth environments. More than 15,000 U.S. urgent care centers collectively manage a very large annual patient population and depend on rapid turnaround to maintain throughput.

Respiratory testing dominates seasonal demand, but broader adoption of chemistry, glucose and other assays could increase POC revenue per site. Retail clinics and pharmacies create additional opportunities when regulations, test waivers and reimbursement align.

Ambulatory Surgery and Specialty Clinics

Ambulatory surgery centers, anticoagulation clinics, dialysis centers and specialty practices use handheld testing when results influence immediate procedure or treatment decisions.

Growth is connected to the continuing migration of procedures from hospitals to outpatient settings. Devices designed for moderate throughput and minimal infrastructure are especially well positioned.

Home Healthcare and Patient Self-Testing

Home healthcare and self-testing remain major markets for glucose and coagulation devices. The longer-term opportunity extends into chronic disease monitoring as connected diagnostic platforms enable clinicians to review results remotely.

Adoption will depend on reimbursement, patient usability and the ability to prevent inaccurate or unnecessary testing.

EMS, Rural and Mobile Care Settings

Emergency medical services, critical-care transport, rural clinics, community health programs and mobile health services represent smaller but strategically important markets. These environments place exceptional value on portability and speed because conventional laboratory access may be limited.

Devices must tolerate transport, variable temperature conditions and non-laboratory operators while maintaining analytical reliability.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Handheld Point-of-Care Testing Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional demand differs according to population growth, diabetes and cardiovascular disease burden, hospital density, urgent care penetration, physician-office laboratory activity, rural access challenges, payer mix and willingness of integrated health systems to decentralize diagnostics.

The South is the largest regional market, while the West is expected to record the fastest growth through 2035. The Northeast has the highest concentration of complex academic healthcare systems and sophisticated diagnostic governance, while the Midwest provides a substantial base of hospital, community and rural POC demand.

South

The South is estimated to account for approximately USD 2.35 billion in 2025, or slightly more than 36% of the national market. The region is projected to reach approximately USD 5.88 billion by 2035, representing a regional CAGR of roughly 9.6%.

Market leadership is supported by population scale, rapid Sun Belt growth, high diabetes and cardiovascular disease burden, significant rural populations and expanding urgent care networks. These characteristics create demand simultaneously at high-acuity urban hospitals and decentralized community settings.

Texas is the region’s most important individual market. Houston, Dallas-Fort Worth, Austin and San Antonio support major health systems, trauma centers and academic institutions that consume large volumes of critical-care cartridges, cardiac tests and hospital glucose testing. Texas also has extensive rural geography, strengthening the case for portable diagnostics in smaller hospitals and community clinics.

Florida represents another major demand center due to its large older-adult population, heavy Medicare utilization and extensive network of hospitals, urgent care facilities and specialty practices. Diabetes, cardiovascular disease, anticoagulation and respiratory illness make glucose, coagulation, cardiac and infectious-disease testing particularly relevant.

North Carolina, Georgia, Virginia, Maryland and Tennessee have attractive growth profiles because of expanding metropolitan populations and sophisticated health systems. Raleigh-Durham, Charlotte, Atlanta, Northern Virginia, Baltimore and Nashville provide strong environments for enterprise adoption of connected POC systems.

North Carolina additionally benefits from life-science infrastructure and large academic networks, while Maryland and Virginia have substantial federal, military and research-linked healthcare activity. Tennessee’s major hospital systems make the state especially relevant for enterprise standardization and procurement contracts.

South Carolina, Alabama, Mississippi, Louisiana, Kentucky, Arkansas, Oklahoma and West Virginia show meaningful need for decentralized diagnostics because chronic disease burden and rural access constraints can be significant. Portable glucose, renal, cardiac, blood gas and infectious-disease testing can provide particular clinical value in community hospitals and clinics distant from full-service laboratories.

Delaware is a smaller market but benefits from integration with Mid-Atlantic health systems. The District of Columbia, while not a state, has a disproportionately sophisticated hospital and academic care environment and contributes to high-acuity POC adoption across the Washington metropolitan market.

The strategic opportunity in the South is therefore split between scale and access. Large metropolitan health systems provide high cartridge volumes, while rural and community sites reward devices that can deliver laboratory-quality results without laboratory infrastructure.

West

The West represents an estimated USD 1.50 billion market in 2025 and is projected to reach approximately USD 3.89 billion by 2035, producing an estimated 10.0% CAGR, the fastest among the four U.S. regions.

The West benefits from technology adoption, digital-health integration, population growth in multiple Sun Belt states and large territories where decentralized testing has operational value.

California is the largest state market in the West and one of the largest nationally. Its scale is supported by a large population, extensive academic medical infrastructure and a strong medtech and digital-health ecosystem. California providers are influential early adopters of connected diagnostics, middleware-enabled POC fleets and decentralized outpatient testing.

Los Angeles, San Diego, San Francisco, Sacramento and other major markets provide substantial inpatient and ambulatory demand. California is also important to manufacturers because health systems can serve as clinical reference sites capable of influencing adoption beyond the state.

Washington and Oregon have mature integrated health systems and strong adoption of digitally connected care. Point-of-care devices that integrate cleanly with enterprise information systems are particularly well aligned with procurement models in these states.

Arizona and Nevada are among the strongest growth opportunities due to population expansion and aging demographics. Phoenix, Tucson, Las Vegas and surrounding communities are experiencing growing demand for hospitals, urgent care, outpatient specialty care and chronic-disease management.

Colorado and Utah combine population growth with sophisticated provider systems. Their markets are particularly attractive for connected POC platforms that can support urban centers as well as geographically distributed satellite clinics.

New Mexico, Idaho, Montana and Wyoming are smaller by revenue but important for decentralized medicine because of lower population density and travel distances. Portable testing has strong value where transporting samples to regional laboratories can delay treatment.

Alaska represents a specialized opportunity where remote healthcare logistics make compact diagnostic capability strategically important despite the state’s smaller population. Hawaii similarly benefits from decentralized diagnostic capability across an island-based healthcare system in which specimen logistics can be more complicated than on the mainland.

The West’s faster growth will be driven by connected diagnostic ecosystems, population migration, outpatient medicine and adoption of advanced multi-assay platforms rather than basic single-analyte testing alone.

Northeast

The Northeast accounted for an estimated USD 1.46 billion in 2025 and is expected to reach approximately USD 3.30 billion by 2035, representing a CAGR of roughly 8.5%.

The region has slower population growth than the South or West but one of the highest concentrations of academic medical centers, major integrated delivery networks and specialized clinical laboratories. Procurement tends to be evidence-intensive, with substantial attention to analytical validation, laboratory governance, cybersecurity and information-system integration.

New York is the largest state market in the Northeast. New York City’s dense hospital infrastructure generates considerable inpatient and emergency testing volume, while the broader state creates additional demand across community, suburban and rural settings.

Pennsylvania and New Jersey form another large POC testing corridor. Philadelphia, Pittsburgh and the dense New Jersey healthcare market support major hospital systems, physician practices and urgent care networks. These states are commercially attractive for standardized multi-site instrument placements.

Massachusetts is disproportionately influential relative to population because of Boston’s academic hospitals, biotechnology ecosystem and concentration of early-adopting specialists. Novel cardiac biomarker, infectious-disease and multiparameter technologies can gain clinical visibility through these institutions.

Connecticut and Rhode Island have compact but relatively high-value healthcare markets with strong links to larger Northeast health systems. Their provider density supports broad decentralized testing deployment.

Maine, New Hampshire and Vermont are smaller markets where rural geography and regional referral patterns increase the usefulness of portable diagnostics in community hospitals, physician offices and emergency care.

The Northeast is expected to remain one of the most strategically valuable regions even with a slightly lower CAGR because successful adoption in major academic systems can provide clinical credibility and reference accounts for nationwide commercialization.

Midwest

The Midwest is estimated at USD 1.17 billion in 2025 and is projected to reach approximately USD 2.70 billion by 2035, representing a CAGR of approximately 8.7%.

The region combines large metropolitan health systems with extensive community and rural healthcare infrastructure. This supports demand for both enterprise-scale hospital POC fleets and portable systems designed for lower-volume locations.

Illinois, Ohio, Michigan and Minnesota are the major state-level markets. Chicago provides a large academic and integrated provider ecosystem. Ohio has substantial hospital and specialty-care infrastructure across Cleveland, Columbus and Cincinnati. Michigan generates significant hospital and chronic-disease testing demand through Detroit and other regional systems.

Minnesota is particularly important because of its medtech heritage and sophisticated healthcare delivery environment. Health systems in the state are strong candidates for connected and analytically advanced POC platforms.

Indiana and Wisconsin provide stable hospital, physician-office and ambulatory testing demand. Both states have broad community healthcare networks where device standardization and service reliability can materially influence purchasing.

Missouri, Iowa and Kansas combine metropolitan medical centers with broad rural catchment areas. Point-of-care testing can help regional hospitals and clinics reduce dependence on specimen transportation for time-sensitive results.

Nebraska, North Dakota and South Dakota are smaller revenue markets but offer a strong use case for portable diagnostics because of rural population distribution and long distances between healthcare facilities. EMS, critical-access hospitals and rural clinics represent particularly relevant deployment settings.

The Midwest is unlikely to outgrow the West or South, but it will remain an important recurring-consumables market. Vendors that provide dependable field service, predictable cartridge economics and strong health-system contracting should perform well across the region.

 

Key Market Players

The U.S. Handheld Point-of-Care Testing Devices competitive landscape is moderately consolidated in high-value hospital platforms but substantially more fragmented across diabetes, infectious disease, coagulation, hemoglobin and specialty testing.

Abbott has one of the strongest positions in handheld acute-care diagnostics through its i-STAT franchise and also possesses a substantial diabetes-testing presence. Roche is strategically important in glucose, coagulation and decentralized diagnostics and has strengthened its platform ambitions through the acquisition of LumiraDx point-of-care technology. Nova Biomedical is highly relevant in hospital glucose and critical-care testing and has increased strategic scale following its combination with Advanced Instruments.

Competition is increasingly being shaped by installed-base economics. Once an analyzer is deployed across an enterprise, validated by the laboratory, connected to middleware, integrated into electronic records and supported through staff training, switching costs rise materially. Manufacturers therefore compete not only for instrument placements but also for the recurring cartridge or strip volume generated over the lifetime of the platform.

Some of the key companies participating directly or indirectly in the U.S. handheld and portable point-of-care testing ecosystem include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Becton, Dickinson and Company, QuidelOrtho Corporation, Nova Biomedical, HemoCue, EKF Diagnostics, ACON Laboratories, ARKRAY USA, LifeScan, Ascensia Diabetes Care, Trividia Health, PTS Diagnostics, SEKISUI Diagnostics, Trinity Biotech, OraSure Technologies, Biosynex/Chembio Diagnostics, OSANG Healthcare, FORA/TaiDoc Technology, i-SENS, AgaMatrix, PixCell Medical and Micropoint Bioscience.

Abbott is positioned strongly in multiparameter acute-care testing, while Roche has the strategic scale to link near-patient testing with its broader diagnostics business. Nova Biomedical remains influential in hospital point-of-care glucose and critical-care analytics. QuidelOrtho is a major player in instrumented rapid infectious-disease testing, while HemoCue is important in portable hemoglobin applications.

LifeScan, Ascensia, Trividia, ARKRAY, ACON, i-SENS and AgaMatrix compete heavily within the handheld glucose ecosystem. PTS Diagnostics addresses cardiometabolic point-of-care applications. EKF Diagnostics participates in portable hemoglobin, HbA1c and related clinical testing. SEKISUI, OraSure, Biosynex/Chembio and OSANG contribute to infectious-disease and rapid diagnostic competition.

Competitive success through 2035 will increasingly depend on five variables: breadth of assay menu, regulatory execution, instrument connectivity, proprietary consumable economics and access to large health-system contracts. Companies with a single strong assay can still gain share, but platform vendors capable of increasing revenue from each installed instrument are structurally better positioned.

 

Recent Developments

Recent activity in the U.S. market highlights increasing investment in portable diagnostics, cardiac testing, decentralized assay menus and platform consolidation.

In June 2026, FDA clearance of Abbott’s i-STAT high-sensitivity troponin I cartridge for the i-STAT Alinity System represented an important advancement for portable cardiac biomarker testing. High-sensitivity troponin is strategically significant because emergency-department chest-pain pathways depend on rapid and analytically robust results. The development illustrates how established handheld platforms can create new economic value through assay expansion rather than relying solely on additional instrument placements.

Abbott also received a U.S. clearance during 2025 involving its i-STAT CG4+ cartridge with the i-STAT 1 System, reinforcing continued regulatory investment in a mature handheld installed base. The broader commercial implication is that established platform manufacturers can defend market share by continuously upgrading assay capabilities while preserving hospital workflow familiarity.

In September 2026, additional CLIA-waived classifications for tests on QuidelOrtho’s Sofia 2 platform expanded decentralized respiratory and infectious-disease testing possibilities, including influenza, RSV, Group A streptococcus and other assays. This reinforces the importance of instrumented rapid testing in urgent care and physician-office environments, where ease of use and waiver status can materially influence adoption.

Roche completed its acquisition of LumiraDx’s point-of-care technology in July 2024, adding a portable multi-assay platform capable of supporting clinical chemistry, immunoassay and coagulation applications. Roche paid approximately USD 353 million for the acquired LumiraDx assets according to its subsequent financial reporting. The strategic significance extends beyond the transaction value: Roche gained a route to a more integrated decentralized-testing portfolio alongside its large central-diagnostics business.

The U.S. market also experienced important consolidation in 2025 when Advanced Instruments completed the acquisition of Nova Biomedical at an enterprise value of approximately USD 2.2 billion. The combined organization subsequently moved under the Nova Biomedical name. The transaction demonstrates the strategic value attributed to recurring analytical instrument and consumable platforms serving clinical and life-science customers.

In infectious disease, the FDA’s 2024 authorization of the first point-of-care hepatitis C RNA testing approach capable of supporting a same-visit test-and-treat pathway demonstrated the direction of decentralized molecular diagnostics. Although compact molecular systems are not always strictly handheld, they are strategically adjacent to the market because successive generations are expected to become smaller, simpler and more appropriate for decentralized settings.

Across the competitive landscape, innovation is therefore moving in a consistent direction: broader assay menus, shorter time to result, fewer operator steps, smaller sample volumes, automatic result transmission and expanded eligibility for decentralized operation.

 

Conclusion

The U.S. Handheld Point-of-Care Testing Devices Market Size & Share is positioned to expand from approximately USD 6.48 billion in 2025 to USD 15.77 billion by 2035, representing a 9.30% CAGR during 2026–2035. Growth will be supported by chronic disease prevalence, emergency-care volumes, expansion of urgent care, the large CLIA-waived testing ecosystem, movement of care into outpatient settings and continued clinical demand for faster diagnostic decisions.

The market’s commercial opportunity is broader than selling portable instruments. Revenue increasingly depends on building an installed base that generates recurring proprietary cartridge, cassette or strip demand. As a result, manufacturers with expandable assay menus, strong instrument uptime and integrated data-management capabilities should capture disproportionate lifetime value from each account.

Blood glucose testing will remain the largest installed category, but faster value growth is expected from multiparameter critical-care systems, cardiac biomarkers, portable infectious-disease platforms and molecular diagnostics. High-sensitivity troponin, miniaturized microfluidics and increasingly automated near-patient molecular testing are particularly important innovation areas.

Hospitals will remain the dominant end users by value, but urgent care, physician offices, specialty clinics and home-centered care will account for an increasing share of incremental placements. The distinction between hospital POC and community POC will also become less pronounced as large integrated health systems standardize common platforms across inpatient and ambulatory networks.

Regionally, the South will remain the largest market, supported by population scale, chronic disease burden and healthcare infrastructure expansion. The West is expected to record the fastest growth, reflecting population migration and strong adoption of connected diagnostic technologies. The Northeast will remain an important premium and early-adoption region, while the Midwest will provide durable hospital, community and rural testing demand.

For manufacturers and investors, one of the most important strategic questions is whether a product solves a sufficiently expensive workflow problem to justify decentralizing the test. Tests that merely reproduce central laboratory capability at a higher unit cost will face purchasing resistance. Tests that shorten treatment decisions, support immediate discharge, improve clinical throughput or allow care to move into a lower-cost setting have a materially stronger value proposition.

For hospital buyers, the decisive factors will increasingly include total cost per reportable result, nursing time, cartridge waste, quality-control burden, operator training, cybersecurity, interface cost and instrument fleet management. A device with a lower purchase price can become economically unattractive if it generates substantial manual workflow or disconnected data.

The next decade will therefore favor companies that combine analytical quality, portable form factor, CLIA-accessible workflows, broad assay menus, recurring consumable economics and enterprise-grade connectivity. The competitive frontier is no longer simply faster testing. It is the creation of a clinically reliable distributed diagnostic network capable of bringing laboratory-quality information to the exact location and moment at which a U.S. clinician must make a treatment decision.

 

TABLE OF CONTENT

1. U.S. Handheld Point-of-Care Testing Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.2.1. Devices Included in the Market Scope
1.2.2. Assay Consumables Included in the Market Scope
1.2.3. Devices and Testing Categories Excluded from the Market Scope
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Market Sizing and Bottom-Up Installed Base Analysis
1.3.6. Analytical Frameworks & Forecasting Models
1.3.7. Data Triangulation, Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Handheld Point-of-Care Device Manufacturers
1.6.2. Assay Cartridge, Strip, Cassette and Reagent Suppliers
1.6.3. Biosensor, Microfluidic and Diagnostic Component Suppliers
1.6.4. Hospitals and Integrated Delivery Networks
1.6.5. Clinical Laboratories and Point-of-Care Coordinators
1.6.6. Physician Offices and Primary Care Practices
1.6.7. Urgent Care Centers and Retail Clinics
1.6.8. Ambulatory and Specialty Care Providers
1.6.9. Home Healthcare and Patient Self-Testing Providers
1.6.10. Group Purchasing Organizations and Diagnostic Distributors
1.6.11. Payers, FDA, CMS and CLIA Regulatory Stakeholders

What this section provides: This section defines the market boundary, device and consumable scope, methodology, assumptions, sizing methodology and stakeholder ecosystem used to measure and validate the U.S. handheld point-of-care testing devices market.

2. U.S. Handheld Point-of-Care Testing Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. U.S. Market Size, 2021–2035 (US$ Billion)
2.8. CAGR Analysis, 2026–2035
2.9. High-Growth Diagnostic Opportunity Areas
2.10. Most Attractive Device and Assay Categories
2.11. Leading Care-Setting Opportunities
2.12. Regional Opportunity Snapshot
2.13. Key Strategic Findings for Manufacturers and Investors

What this section provides: This section gives decision-makers a concise view of U.S. market size, CAGR, historical performance, forecast direction, leading diagnostic categories, care-setting opportunities and strategic growth pockets through 2035.

3. U.S. Handheld Point-of-Care Testing Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Diabetes and Chronic Disease Testing Burden
3.1.2. Growing Demand for Rapid Clinical Decision-Making
3.1.3. High Emergency Department and Critical-Care Testing Volumes
3.1.4. Expansion of CLIA-Waived Testing Sites
3.1.5. Rapid Growth of Urgent Care and Decentralized Ambulatory Diagnostics
3.1.6. Shift of Healthcare Delivery Toward Outpatient and Community Settings
3.1.7. Rising Adoption of Connected Point-of-Care Diagnostic Platforms
3.1.8. Growing Need for Rapid Infectious-Disease Differentiation
3.1.9. Expansion of Home-Based and Remote Chronic Disease Management

3.2. Restraints and Their Impact Analysis
3.2.1. Higher Cost per Test Compared with Central Laboratory Testing
3.2.2. Point-of-Care Quality Control and Compliance Burden
3.2.3. Operator Variability and Pre-Analytical Error Risk
3.2.4. Device Connectivity and Cybersecurity Requirements
3.2.5. Reimbursement Variability Across Decentralized Testing Settings
3.2.6. Competition from Central Laboratories and Continuous Monitoring Technologies

3.3. Opportunities and Their Impact Analysis
3.3.1. Handheld High-Sensitivity Cardiac Troponin Testing
3.3.2. Miniaturized Molecular Point-of-Care Diagnostics
3.3.3. Multiplex Respiratory and Infectious-Disease Testing
3.3.4. Microfluidic Multiparameter Diagnostic Platforms
3.3.5. Connected Device and Electronic Health Record Integration
3.3.6. Rural, EMS and Critical-Access Hospital Testing
3.3.7. Expansion of CLIA-Waived Assay Menus
3.3.8. Home and Patient Self-Testing Platforms

3.4. Challenges and Their Impact Analysis
3.4.1. Clinical Validation Across Diverse Testing Environments
3.4.2. Managing Large Distributed Device Fleets
3.4.3. Maintaining Operator Competency
3.4.4. Cartridge and Consumable Supply Reliability
3.4.5. Ensuring Laboratory Governance Outside the Central Lab

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.6.1. Time-to-Result Economics
3.6.2. Emergency Department Throughput Impact
3.6.3. Avoided Sample Transportation and Processing Costs
3.6.4. Same-Visit Diagnosis and Treatment Economics
3.6.5. Cost per Reportable Result Analysis

3.7. Hospital and Health System Procurement Behavior Analysis
3.7.1. Instrument Versus Consumable Economics
3.7.2. Installed-Base and Recurring Cartridge Revenue Model
3.7.3. Enterprise Standardization of Point-of-Care Platforms
3.7.4. Point-of-Care Coordinator Influence on Purchasing
3.7.5. Value Analysis Committee Decision Criteria

What this section provides: This section explains the clinical, commercial, workflow, reimbursement and operational forces affecting handheld POC testing demand and identifies the highest-impact opportunities and adoption barriers.

4. U.S. Handheld Point-of-Care Testing Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis, 2025–2035
4.3.1. Instrument Pricing Trends
4.3.2. Cartridge and Consumable Pricing Trends
4.3.3. Cost per Test Trends
4.3.4. Regional Pricing Variation

4.4. Value Chain & Supply Chain Analysis
4.4.1. Biosensor and Reagent Suppliers
4.4.2. Diagnostic Component Manufacturers
4.4.3. Device Manufacturers
4.4.4. Cartridge and Consumable Manufacturing
4.4.5. Diagnostic Distributors and GPOs
4.4.6. Healthcare Provider Customers

4.5. Impact of Digitalization and Connected Diagnostics
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. FDA 510(k) Pathway
4.7.2. De Novo Classification Pathway
4.7.3. Premarket Approval Considerations
4.7.4. Emergency Use Authorization Legacy Impact
4.7.5. Post-Market Surveillance Requirements

4.8. CLIA Regulatory Landscape
4.8.1. CLIA-Waived Testing
4.8.2. Moderate-Complexity Testing
4.8.3. Operator and Quality-Control Requirements
4.8.4. Impact of CLIA Waiver on Addressable Market

4.9. CMS Reimbursement and Coverage Landscape
4.9.1. Clinical Laboratory Fee Schedule Considerations
4.9.2. Physician Office Testing Reimbursement
4.9.3. Hospital Outpatient Economics
4.9.4. Home and Self-Testing Reimbursement

4.10. Import/Export Restrictions & Tariff Impact
4.11. Government Initiatives and Public Health Programs
4.12. Impact of Escalating Geopolitical Tensions
4.13. Diagnostic Supply Chain Resilience Analysis
4.14. Hospital Value Analysis Committee Decision Framework

What this section provides: This section gives clients a comprehensive view of regulation, CLIA requirements, reimbursement, pricing, supply chain, connectivity, competitive pressure and purchasing criteria influencing the U.S. handheld POC testing ecosystem.

5. U.S. Handheld Point-of-Care Testing Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)

5.2. Handheld Blood Glucose and Metabolic Meters
5.2.1. Professional Blood Glucose Meters
5.2.2. Patient Self-Testing Blood Glucose Meters
5.2.3. Blood Ketone Meters
5.2.4. Multiparameter Glucose and Metabolic Meters

5.3. Handheld Blood Gas, Electrolyte and Lactate Analyzers
5.3.1. Blood Gas Analyzers
5.3.2. Electrolyte Analyzers
5.3.3. Lactate Analyzers
5.3.4. Combined Blood Gas and Chemistry Systems

5.4. Handheld Coagulation and INR Devices
5.4.1. PT/INR Meters
5.4.2. Activated Clotting Time Systems
5.4.3. Other Portable Coagulation Testing Systems

5.5. Cardiac Biomarker and Critical-Care Handheld Systems
5.5.1. Troponin Testing Devices
5.5.2. BNP/NT-proBNP Testing Devices
5.5.3. D-Dimer Testing Devices
5.5.4. Multiparameter Critical-Care Systems

5.6. Portable Infectious-Disease Readers and Molecular POC Systems
5.6.1. Instrumented Antigen Readers
5.6.2. Fluorescence Immunoassay Readers
5.6.3. Portable Molecular Testing Systems
5.6.4. Multiplex Infectious-Disease Platforms

5.7. Handheld Hemoglobin and Hematology Devices
5.7.1. Hemoglobin Meters
5.7.2. Hematocrit Testing Devices
5.7.3. Portable CBC and Hematology Systems

5.8. Other Multiparameter Chemistry and Specialty POC Devices
5.8.1. Lipid Testing Devices
5.8.2. Renal Function Testing Devices
5.8.3. Urinalysis Readers
5.8.4. Specialty Chemistry Devices
5.8.5. Other Portable Diagnostic Platforms

What this section provides: This section identifies which handheld POC device categories generate the largest revenue pools, recurring consumable opportunities and strongest growth potential through 2035.

6. U.S. Handheld Point-of-Care Testing Devices Market – By Clinical Test Category

6.1. Overview
6.1.1. Segment Share Analysis, By Clinical Test Category, 2025 & 2035 (%)
6.1.2. Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)

6.2. Glucose, HbA1c and Ketone Testing
6.2.1. Blood Glucose
6.2.2. HbA1c
6.2.3. Blood Ketones

6.3. Blood Gas, Electrolyte and Lactate Testing
6.3.1. pH and Blood Gases
6.3.2. Sodium and Potassium
6.3.3. Ionized Calcium
6.3.4. Lactate
6.3.5. Other Critical-Care Chemistries

6.4. Coagulation Testing
6.4.1. PT/INR
6.4.2. Activated Clotting Time
6.4.3. Other Coagulation Parameters

6.5. Cardiac Biomarker Testing
6.5.1. Troponin
6.5.2. BNP/NT-proBNP
6.5.3. CK-MB
6.5.4. D-Dimer
6.5.5. Other Cardiac and Vascular Biomarkers

6.6. Infectious-Disease Testing
6.6.1. Influenza
6.6.2. SARS-CoV-2
6.6.3. Respiratory Syncytial Virus
6.6.4. Group A Streptococcus
6.6.5. Sexually Transmitted Infections
6.6.6. Hepatitis and Blood-Borne Infections
6.6.7. Multiplex Respiratory Panels
6.6.8. Other Infectious Diseases

6.7. Hemoglobin, Hematocrit and Anemia Testing
6.7.1. Hemoglobin
6.7.2. Hematocrit
6.7.3. Anemia Screening

6.8. Lipid, Renal and Other Chemistry Testing
6.8.1. Lipid Profiles
6.8.2. Creatinine and Renal Function
6.8.3. General Chemistry
6.8.4. Other Specialty Tests

What this section provides: This section quantifies demand by diagnostic use case and helps clients identify assay categories with high testing frequency, clinical urgency, reimbursement relevance and decentralization potential.

7. U.S. Handheld Point-of-Care Testing Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

7.2. Hospitals and Health Systems
7.2.1. Emergency Departments
7.2.2. Intensive and Critical Care Units
7.2.3. Operating Rooms and Perioperative Care
7.2.4. Inpatient Nursing Units
7.2.5. Labor and Delivery Units

7.3. Physician Offices and Primary Care Practices
7.3.1. Family and Internal Medicine Practices
7.3.2. Endocrinology and Diabetes Practices
7.3.3. Cardiology Practices
7.3.4. Pediatric Practices
7.3.5. Other Physician Office Laboratories

7.4. Urgent Care, Retail Clinics and Pharmacies
7.4.1. Urgent Care Centers
7.4.2. Retail Health Clinics
7.4.3. Pharmacy-Based Testing Sites

7.5. Ambulatory Surgery and Specialty Clinics
7.5.1. Ambulatory Surgery Centers
7.5.2. Anticoagulation Clinics
7.5.3. Dialysis Centers
7.5.4. Specialty Treatment Centers

7.6. Home Healthcare and Patient Self-Testing
7.6.1. Home Healthcare Agencies
7.6.2. Diabetes Self-Testing
7.6.3. INR Self-Testing
7.6.4. Remote Chronic Disease Monitoring

7.7. EMS, Rural and Mobile Care Settings
7.7.1. Emergency Medical Services
7.7.2. Critical-Access Hospitals
7.7.3. Rural Health Clinics
7.7.4. Community Health Centers
7.7.5. Mobile Healthcare Services

What this section provides: This section evaluates purchasing and utilization across hospitals, physician offices, urgent care, ambulatory care, home testing, EMS and rural healthcare environments.

8. U.S. Handheld Point-of-Care Testing Devices Market – By Technology

8.1. Overview
8.1.1. Segment Share Analysis, By Technology, 2025 & 2035 (%)
8.1.2. Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

8.2. Electrochemical Biosensor Technology
8.2.1. Amperometric Sensors
8.2.2. Potentiometric Sensors
8.2.3. Other Electrochemical Sensors

8.3. Optical and Photometric Technology
8.3.1. Reflectance Photometry
8.3.2. Absorbance Photometry
8.3.3. Spectrophotometric Detection

8.4. Immunoassay and Fluorescence Reader Technology
8.4.1. Fluorescence Immunoassay
8.4.2. Lateral Flow Reader Systems
8.4.3. Chemiluminescence-Based Portable Systems

8.5. Molecular and Nucleic-Acid Amplification Technology
8.5.1. PCR-Based POC Systems
8.5.2. Isothermal Amplification
8.5.3. Other Miniaturized Molecular Technologies

8.6. Microfluidic and Lab-on-Chip Technology
8.6.1. Cartridge-Based Microfluidic Systems
8.6.2. Multiplex Lab-on-Chip Systems
8.6.3. Integrated Sample-to-Answer Systems

8.7. Digitally Connected Multiparameter Platforms
8.7.1. Bluetooth-Enabled Devices
8.7.2. Wi-Fi-Enabled Devices
8.7.3. Middleware-Connected POC Platforms
8.7.4. Cloud-Connected Diagnostic Systems
8.7.5. EHR-Integrated Point-of-Care Devices

What this section provides: This section evaluates the technologies shaping the competitive landscape, including biosensors, microfluidics, optical detection, immunoassays, molecular diagnostics and digitally connected multiparameter platforms.

9. U.S. Handheld Point-of-Care Testing Devices Market: Procurement, Reimbursement & Commercial Access Analysis

9.1. U.S. Diagnostic Procurement Ecosystem
9.2. Direct Hospital and Health System Procurement
9.3. Integrated Delivery Network Enterprise Contracts
9.4. Group Purchasing Organization Influence
9.5. Diagnostic Distributor and Specialty Supplier Channels
9.6. Physician Office and Urgent Care Procurement Models
9.7. Retail and Pharmacy Diagnostic Procurement
9.8. Instrument Placement Versus Direct Purchase Models
9.9. Reagent Rental and Consumable-Tied Instrument Models
9.10. Cost-per-Test Contracting Models
9.11. Installed-Base Economics
9.12. Cartridge Pull-Through and Recurring Revenue Analysis
9.13. Hospital Value Analysis Committee Requirements
9.14. Laboratory Director and POC Coordinator Purchasing Influence
9.15. CLIA Waiver as a Commercial Access Driver
9.16. Reimbursement Sensitivity by Testing Environment
9.17. Vendor Consolidation and Platform Standardization Trends
9.18. Service, Training and Connectivity Requirements
9.19. Switching Costs and Contract Renewal Dynamics

What this section provides: This section explains how handheld POC systems reach U.S. customers, how instrument and consumable contracts are structured, and how reimbursement, CLIA status, GPOs and IDN standardization influence commercial access.

10. U.S. Handheld Point-of-Care Testing Devices Market – By Geography

10.1. Introduction

10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional POC Testing Volume and Healthcare Infrastructure Analysis
10.1.4. Regional CLIA-Waived Testing Site Analysis
10.1.5. Regional Hospital and Urgent Care Infrastructure Analysis
10.1.6. Regional Chronic Disease and Diagnostic Demand Analysis
10.1.7. Regional Reimbursement and Procurement Dynamics
10.1.8. Regional Adoption of Connected and Decentralized Diagnostics

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers and Distribution Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.2.8. West Region POC Infrastructure, CLIA-Waived Site and Adoption Analysis

10.2.9. California

10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.10. Washington

10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.11. Arizona

10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.12. Colorado

10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.13. Oregon

10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.14. Utah

10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.15. Nevada

10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.16. New Mexico

10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.17. Idaho

10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.18. Montana

10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.19. Wyoming

10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.20. Alaska

10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.2.21. Hawaii

10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers and Distribution Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.3.8. Northeast Region POC Infrastructure, CLIA-Waived Site and Adoption Analysis

10.3.9. New York

10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3.10. Massachusetts

10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3.11. New Jersey

10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania

10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3.13. Connecticut

10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3.14. Maine

10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3.15. Vermont

10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3.16. New Hampshire

10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3.17. Rhode Island

10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.3.18. Delaware

10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers and Distribution Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.4.8. South Region POC Infrastructure, CLIA-Waived Site and Adoption Analysis

10.4.9. Texas

10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.10. Florida

10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.11. Georgia

10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.12. North Carolina

10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.13. Tennessee

10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.14. South Carolina

10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.15. Alabama

10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.16. Mississippi

10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.17. Louisiana

10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.18. Arkansas

10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.19. Kentucky

10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.20. Oklahoma

10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.21. Virginia

10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.22. Maryland

10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.4.23. West Virginia

10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers and Distribution Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)
10.5.8. Midwest Region POC Infrastructure, CLIA-Waived Site and Adoption Analysis

10.5.9. Illinois

10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.10. Ohio

10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.11. Michigan

10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.12. Minnesota

10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.13. Indiana

10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.14. Wisconsin

10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.15. Missouri

10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.16. Iowa

10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.17. Kansas

10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.18. Nebraska

10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.19. North Dakota

10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

10.5.20. South Dakota

10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Clinical Test Category, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and all-50-state analysis, enabling clients to identify POC diagnostic demand clusters, CLIA-waived testing hotspots, health-system opportunities, decentralized testing adoption and state-level commercial priorities.

11. U.S. Handheld Point-of-Care Testing Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking
11.2.1. Product Portfolio Breadth
11.2.2. Installed Instrument Base
11.2.3. Proprietary Consumable Exposure
11.2.4. Assay Menu Breadth
11.2.5. CLIA-Waived Product Portfolio
11.2.6. Connectivity and Middleware Capability
11.2.7. U.S. Distribution Reach
11.2.8. Regulatory Pipeline Strength

11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players

11.4. Company Profiles

11.4.1. Abbott Laboratories
11.4.2. Roche Diagnostics
11.4.3. Siemens Healthineers
11.4.4. Becton, Dickinson and Company
11.4.5. QuidelOrtho Corporation
11.4.6. Nova Biomedical
11.4.7. HemoCue
11.4.8. EKF Diagnostics Holdings
11.4.9. ACON Laboratories
11.4.10. ARKRAY USA
11.4.11. LifeScan
11.4.12. Ascensia Diabetes Care
11.4.13. Trividia Health
11.4.14. PTS Diagnostics
11.4.15. SEKISUI Diagnostics
11.4.16. Trinity Biotech
11.4.17. OraSure Technologies
11.4.18. Chembio Diagnostics Systems / Biosynex
11.4.19. OSANG Healthcare
11.4.20. i-SENS
11.4.21. AgaMatrix
11.4.22. PixCell Medical
11.4.23. Micropoint Bioscience
11.4.24. TaiDoc Technology / FORA
11.4.25. Werfen

11.5. Company Profile Framework
11.5.1. Company Overview
11.5.2. Handheld POC Testing Product Portfolio
11.5.3. Key Assays and Consumables
11.5.4. U.S. Commercial Presence
11.5.5. Installed-Base and Platform Strategy
11.5.6. Financial Positioning
11.5.7. R&D and Innovation Pipeline
11.5.8. FDA and CLIA-Waiver Developments
11.5.9. Partnerships, Acquisitions and Distribution Agreements
11.5.10. Recent Developments

What this section provides: This section provides competitor benchmarking, market positioning, assay and platform comparison, installed-base intelligence and strategic profiles of leading handheld POC testing companies operating in the U.S.

12. U.S. Handheld Point-of-Care Testing Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario

12.2. Disruptive Technologies Impact
12.2.1. High-Sensitivity Handheld Cardiac Biomarker Testing
12.2.2. Miniaturized Molecular Diagnostics
12.2.3. Microfluidic Multiparameter Cartridges
12.2.4. Lab-on-Chip Platforms
12.2.5. Connected POC Ecosystems
12.2.6. AI-Assisted Result Interpretation and Quality Control
12.2.7. Cloud-Based POC Fleet Management
12.2.8. Home-Based Multiparameter Diagnostics

12.3. Future of CLIA-Waived Testing
12.4. Future of Decentralized Laboratory Medicine
12.5. Central Laboratory Versus Point-of-Care Testing Outlook
12.6. Emerging Business Models
12.6.1. Reagent Rental
12.6.2. Instrument Placement Models
12.6.3. Subscription and Connectivity Services
12.6.4. Per-Test Pricing Models

12.7. Business Opportunities for Startups and Existing Players
12.8. Investment Prioritization Matrix
12.9. White-Space Analysis
12.10. Most Attractive Assay Expansion Opportunities
12.11. U.S. Market Outlook Beyond 2035

What this section provides: This section prepares clients for technology disruption, assay decentralization, competitive changes and investment opportunities that could reshape the U.S. handheld POC testing market through 2035.

13. U.S. Handheld Point-of-Care Testing Devices Market: Strategic Recommendations

13.1. Recommendations for Point-of-Care Device Manufacturers
13.2. Recommendations for Diagnostic Assay and Consumable Companies
13.3. Recommendations for Hospitals and Integrated Delivery Networks
13.4. Recommendations for Clinical Laboratories and POC Coordinators
13.5. Recommendations for Physician Offices and Urgent Care Operators
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for Diagnostic Distributors and Channel Partners
13.8. Recommendations for New Entrants and Startups
13.9. Go-to-Market Strategy Considerations
13.10. FDA and CLIA-Waiver Commercialization Strategy
13.11. Assay Menu Expansion Strategy
13.12. Installed-Base Expansion Strategy
13.13. Product Positioning and Portfolio Expansion Guidance
13.14. Regional Commercial Prioritization
13.15. Hospital Contracting and GPO Strategy
13.16. Digital Connectivity and Data Integration Strategy

What this section provides: This section translates market intelligence into practical strategic guidance for manufacturers, investors, laboratories, providers, distributors and new entrants seeking to compete in the U.S. handheld point-of-care testing devices market.

14. U.S. Handheld Point-of-Care Testing Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Market Definition and Product Inclusion Limitation
14.3. Data Use Limitation
14.4. Market Sizing Limitation
14.5. Forecasting Limitation
14.6. State-Level Estimation Limitation
14.7. Regulatory and Reimbursement Information Limitation
14.8. Company and Competitive Intelligence Limitation
14.9. Legal Disclaimer
14.10. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s market boundaries, state-level estimation methodology, forecasting limitations, regulatory considerations, data-use restrictions and legal limitations.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Handheld Point-of-Care Testing Devices Market: Market Definition and Scope
TABLE 3: U.S. Handheld Point-of-Care Testing Devices Market: Research Methodology Framework
TABLE 4: U.S. Handheld Point-of-Care Testing Devices Market: Key Assumptions
TABLE 5: U.S. Handheld Point-of-Care Testing Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Handheld Point-of-Care Testing Devices Market: Stakeholder Analysis
TABLE 7: U.S. Handheld Point-of-Care Testing Devices Market: Device and Consumable Scope Framework
TABLE 8: U.S. Handheld Point-of-Care Testing Devices Market: Executive Summary Snapshot, 2025
TABLE 9: U.S. Handheld Point-of-Care Testing Devices Market: Analyst Viewpoint Summary
TABLE 10: U.S. Handheld Point-of-Care Testing Devices Market: Market Attractiveness Index
TABLE 11: U.S. Handheld Point-of-Care Testing Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 12: U.S. Handheld Point-of-Care Testing Devices Market: Base Year Market Positioning, 2025
TABLE 13: U.S. Handheld Point-of-Care Testing Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 14: U.S. Handheld Point-of-Care Testing Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 15: U.S. Handheld Point-of-Care Testing Devices Market: High-Growth Opportunity Areas
TABLE 16: U.S. Handheld Point-of-Care Testing Devices Market: Drivers; Impact Analysis
TABLE 17: U.S. Handheld Point-of-Care Testing Devices Market: Restraints; Impact Analysis
TABLE 18: U.S. Handheld Point-of-Care Testing Devices Market: Opportunities; Impact Analysis
TABLE 19: U.S. Handheld Point-of-Care Testing Devices Market: Challenges; Impact Analysis
TABLE 20: U.S. Handheld Point-of-Care Testing Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 21: U.S. Handheld Point-of-Care Testing Devices Market: Clinical Workflow Economics Matrix
TABLE 22: U.S. Handheld Point-of-Care Testing Devices Market: Time-to-Result Economics Analysis
TABLE 23: U.S. Handheld Point-of-Care Testing Devices Market: Cost-per-Reportable-Result Analysis
TABLE 24: U.S. Handheld Point-of-Care Testing Devices Market: Hospital and Health System Procurement Behavior Matrix
TABLE 25: U.S. Handheld Point-of-Care Testing Devices Market: PESTEL Analysis
TABLE 26: U.S. Handheld Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
TABLE 27: U.S. Handheld Point-of-Care Testing Devices Market: Pricing Trend Analysis, 2025–2035
TABLE 28: U.S. Handheld Point-of-Care Testing Devices Market: Instrument Pricing Trends
TABLE 29: U.S. Handheld Point-of-Care Testing Devices Market: Cartridge and Consumable Pricing Trends
TABLE 30: U.S. Handheld Point-of-Care Testing Devices Market: Value Chain Analysis
TABLE 31: U.S. Handheld Point-of-Care Testing Devices Market: Supply Chain Analysis
TABLE 32: U.S. Handheld Point-of-Care Testing Devices Market: Digitalization and Connected Diagnostics Impact
TABLE 33: U.S. Handheld Point-of-Care Testing Devices Market: Application & Innovation Landscape
TABLE 34: U.S. Handheld Point-of-Care Testing Devices Market: FDA Regulatory Framework Analysis
TABLE 35: U.S. Handheld Point-of-Care Testing Devices Market: CLIA Regulatory and Waiver Landscape
TABLE 36: U.S. Handheld Point-of-Care Testing Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 37: U.S. Handheld Point-of-Care Testing Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 38: U.S. Handheld Point-of-Care Testing Devices Market: Government Initiatives and Public Health Programs
TABLE 39: U.S. Handheld Point-of-Care Testing Devices Market: Diagnostic Supply Chain Resilience Analysis
TABLE 40: U.S. Handheld Point-of-Care Testing Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 41: U.S. Handheld Point-of-Care Testing Devices Market: Product Type Snapshot, 2025
TABLE 42: Segment Dashboard; Definition and Scope, by Product Type
TABLE 43: U.S. Handheld Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 44: U.S. Handheld Point-of-Care Testing Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 45: Handheld Blood Glucose and Metabolic Meters Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: Handheld Blood Gas, Electrolyte and Lactate Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: Handheld Coagulation and INR Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: Cardiac Biomarker and Critical-Care Handheld Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: Portable Infectious-Disease Readers and Molecular POC Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: Handheld Hemoglobin and Hematology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Other Multiparameter Chemistry and Specialty POC Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Handheld Point-of-Care Testing Devices Market: Clinical Test Category Snapshot, 2025
TABLE 53: Segment Dashboard; Definition and Scope, by Clinical Test Category
TABLE 54: U.S. Handheld Point-of-Care Testing Devices Market, by Clinical Test Category, 2021–2035 (US$ Billion)
TABLE 55: U.S. Handheld Point-of-Care Testing Devices Market: Segment Share Analysis, by Clinical Test Category, 2025 & 2035 (%)
TABLE 56: Glucose, HbA1c and Ketone Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: Blood Gas, Electrolyte and Lactate Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: Coagulation Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: Cardiac Biomarker Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: Infectious-Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Hemoglobin, Hematocrit and Anemia Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: Lipid, Renal and Other Chemistry Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Handheld Point-of-Care Testing Devices Market: End User Snapshot, 2025
TABLE 64: Segment Dashboard; Definition and Scope, by End User
TABLE 65: U.S. Handheld Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 66: U.S. Handheld Point-of-Care Testing Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 67: Hospitals and Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: Physician Offices and Primary Care Practices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Urgent Care, Retail Clinics and Pharmacies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: Ambulatory Surgery and Specialty Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Home Healthcare and Patient Self-Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: EMS, Rural and Mobile Care Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Handheld Point-of-Care Testing Devices Market: Technology Snapshot, 2025
TABLE 74: Segment Dashboard; Definition and Scope, by Technology
TABLE 75: U.S. Handheld Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 76: U.S. Handheld Point-of-Care Testing Devices Market: Segment Share Analysis, by Technology, 2025 & 2035 (%)
TABLE 77: Electrochemical Biosensor Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: Optical and Photometric Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: Immunoassay and Fluorescence Reader Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: Molecular and Nucleic-Acid Amplification Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: Microfluidic and Lab-on-Chip Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: Digitally Connected Multiparameter Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. Handheld Point-of-Care Testing Devices Market: Diagnostic Procurement Ecosystem
TABLE 84: U.S. Handheld Point-of-Care Testing Devices Market: Hospital and IDN Procurement Models
TABLE 85: U.S. Handheld Point-of-Care Testing Devices Market: GPO and Distributor Channel Analysis
TABLE 86: U.S. Handheld Point-of-Care Testing Devices Market: Physician Office, Urgent Care and Retail Procurement Models
TABLE 87: U.S. Handheld Point-of-Care Testing Devices Market: Instrument Placement vs. Direct Purchase Models
TABLE 88: U.S. Handheld Point-of-Care Testing Devices Market: Reagent Rental and Consumable-Tied Instrument Models
TABLE 89: U.S. Handheld Point-of-Care Testing Devices Market: Cost-per-Test Contracting Models
TABLE 90: U.S. Handheld Point-of-Care Testing Devices Market: Installed-Base and Cartridge Pull-Through Economics
TABLE 91: U.S. Handheld Point-of-Care Testing Devices Market: CLIA Waiver and Commercial Access Matrix
TABLE 92: U.S. Handheld Point-of-Care Testing Devices Market: Reimbursement Sensitivity by Testing Environment
TABLE 93: U.S. Handheld Point-of-Care Testing Devices Market: Vendor Standardization and Switching Cost Analysis
TABLE 94: U.S. Handheld Point-of-Care Testing Devices Market: Service, Training and Connectivity Requirement Matrix
TABLE 95: U.S. Handheld Point-of-Care Testing Devices Market: Regional Snapshot, 2025
TABLE 96: Segment Dashboard; Definition and Scope, by Geography
TABLE 97: U.S. Handheld Point-of-Care Testing Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 98: U.S. Handheld Point-of-Care Testing Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 99: U.S. Handheld Point-of-Care Testing Devices Market: Regional POC Infrastructure and CLIA-Waived Testing Analysis
TABLE 100: U.S. Handheld Point-of-Care Testing Devices Market: Regional Hospital, Urgent Care and Physician Office Infrastructure
TABLE 101: West Region U.S. Handheld Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 102: West Region U.S. Handheld Point-of-Care Testing Devices Market: Key Manufacturers and Distribution Ecosystem
TABLE 103: West Region U.S. Handheld Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 104: West Region U.S. Handheld Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 105: West Region U.S. Handheld Point-of-Care Testing Devices Market, by Clinical Test Category, 2021–2035 (US$ Billion)
TABLE 106: West Region U.S. Handheld Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 107: West Region U.S. Handheld Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 108: California Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Washington Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Arizona Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Colorado Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: Oregon Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Utah Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Nevada Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: New Mexico Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: Idaho Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Montana Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Wyoming Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Alaska Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Hawaii Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Northeast Region U.S. Handheld Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 122: Northeast Region U.S. Handheld Point-of-Care Testing Devices Market: Key Manufacturers and Distribution Ecosystem
TABLE 123: Northeast Region U.S. Handheld Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 124: Northeast Region U.S. Handheld Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 125: Northeast Region U.S. Handheld Point-of-Care Testing Devices Market, by Clinical Test Category, 2021–2035 (US$ Billion)
TABLE 126: Northeast Region U.S. Handheld Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 127: Northeast Region U.S. Handheld Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 128: New York Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Massachusetts Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: New Jersey Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Pennsylvania Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Connecticut Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: Maine Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Vermont Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: New Hampshire Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Rhode Island Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Delaware Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: South Region U.S. Handheld Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 139: South Region U.S. Handheld Point-of-Care Testing Devices Market: Key Manufacturers and Distribution Ecosystem
TABLE 140: South Region U.S. Handheld Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 141: South Region U.S. Handheld Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 142: South Region U.S. Handheld Point-of-Care Testing Devices Market, by Clinical Test Category, 2021–2035 (US$ Billion)
TABLE 143: South Region U.S. Handheld Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 144: South Region U.S. Handheld Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 145: Texas Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Florida Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Georgia Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: North Carolina Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: Tennessee Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: South Carolina Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 151: Alabama Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Mississippi Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Louisiana Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Arkansas Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Kentucky Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Oklahoma Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Virginia Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Maryland Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: West Virginia Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Midwest Region U.S. Handheld Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 161: Midwest Region U.S. Handheld Point-of-Care Testing Devices Market: Key Manufacturers and Distribution Ecosystem
TABLE 162: Midwest Region U.S. Handheld Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 163: Midwest Region U.S. Handheld Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 164: Midwest Region U.S. Handheld Point-of-Care Testing Devices Market, by Clinical Test Category, 2021–2035 (US$ Billion)
TABLE 165: Midwest Region U.S. Handheld Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 166: Midwest Region U.S. Handheld Point-of-Care Testing Devices Market, by Technology, 2021–2035 (US$ Billion)
TABLE 167: Illinois Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 168: Ohio Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 169: Michigan Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 170: Minnesota Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 171: Indiana Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 172: Wisconsin Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 173: Missouri Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 174: Iowa Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 175: Kansas Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 176: Nebraska Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 177: North Dakota Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 178: South Dakota Handheld Point-of-Care Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 179: U.S. Handheld Point-of-Care Testing Devices Market: Competitive Landscape Snapshot, 2025
TABLE 180: U.S. Handheld Point-of-Care Testing Devices Market: Key Company Market Share Analysis, 2025
TABLE 181: U.S. Handheld Point-of-Care Testing Devices Market: Company Positioning Matrix
TABLE 182: U.S. Handheld Point-of-Care Testing Devices Market: Product and Assay Portfolio Benchmarking
TABLE 183: U.S. Handheld Point-of-Care Testing Devices Market: Installed Base, CLIA Waiver and Connectivity Benchmarking
TABLE 184: U.S. Handheld Point-of-Care Testing Devices Market: Regulatory Pipeline Benchmarking of Key Players
TABLE 185: U.S. Handheld Point-of-Care Testing Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 186: Abbott Laboratories: Company Profile
TABLE 187: Roche Diagnostics: Company Profile
TABLE 188: Siemens Healthineers: Company Profile
TABLE 189: Becton, Dickinson and Company: Company Profile
TABLE 190: QuidelOrtho Corporation: Company Profile
TABLE 191: Nova Biomedical: Company Profile
TABLE 192: HemoCue: Company Profile
TABLE 193: EKF Diagnostics Holdings: Company Profile
TABLE 194: ACON Laboratories: Company Profile
TABLE 195: ARKRAY USA: Company Profile
TABLE 196: LifeScan: Company Profile
TABLE 197: Ascensia Diabetes Care: Company Profile
TABLE 198: Trividia Health: Company Profile
TABLE 199: PTS Diagnostics: Company Profile
TABLE 200: SEKISUI Diagnostics: Company Profile
TABLE 201: Trinity Biotech: Company Profile
TABLE 202: OraSure Technologies: Company Profile
TABLE 203: Chembio Diagnostics Systems / Biosynex: Company Profile
TABLE 204: OSANG Healthcare: Company Profile
TABLE 205: i-SENS: Company Profile
TABLE 206: AgaMatrix: Company Profile
TABLE 207: PixCell Medical: Company Profile
TABLE 208: Micropoint Bioscience: Company Profile
TABLE 209: TaiDoc Technology / FORA: Company Profile
TABLE 210: Werfen: Company Profile
TABLE 211: U.S. Handheld Point-of-Care Testing Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 212: U.S. Handheld Point-of-Care Testing Devices Market: Disruptive Technologies Impact Matrix
TABLE 213: U.S. Handheld Point-of-Care Testing Devices Market: High-Sensitivity Cardiac Testing Opportunity
TABLE 214: U.S. Handheld Point-of-Care Testing Devices Market: Miniaturized Molecular Diagnostics Opportunity
TABLE 215: U.S. Handheld Point-of-Care Testing Devices Market: Microfluidic and Lab-on-Chip Opportunity
TABLE 216: U.S. Handheld Point-of-Care Testing Devices Market: Future of CLIA-Waived Testing
TABLE 217: U.S. Handheld Point-of-Care Testing Devices Market: Central Laboratory vs. POC Testing Outlook
TABLE 218: U.S. Handheld Point-of-Care Testing Devices Market: Emerging Business Models
TABLE 219: U.S. Handheld Point-of-Care Testing Devices Market: Business Opportunities for Startups and Existing Players
TABLE 220: U.S. Handheld Point-of-Care Testing Devices Market: White-Space and Assay Expansion Opportunities
TABLE 221: U.S. Handheld Point-of-Care Testing Devices Market: Investment Prioritization Matrix
TABLE 222: U.S. Handheld Point-of-Care Testing Devices Market: Strategic Recommendations for POC Device Manufacturers
TABLE 223: U.S. Handheld Point-of-Care Testing Devices Market: Strategic Recommendations for Assay and Consumable Companies
TABLE 224: U.S. Handheld Point-of-Care Testing Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 225: U.S. Handheld Point-of-Care Testing Devices Market: Strategic Recommendations for Laboratories and POC Coordinators
TABLE 226: U.S. Handheld Point-of-Care Testing Devices Market: Strategic Recommendations for Physician Offices and Urgent Care Operators
TABLE 227: U.S. Handheld Point-of-Care Testing Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 228: U.S. Handheld Point-of-Care Testing Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 229: U.S. Handheld Point-of-Care Testing Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 230: U.S. Handheld Point-of-Care Testing Devices Market: Go-to-Market Strategy Considerations
TABLE 231: U.S. Handheld Point-of-Care Testing Devices Market: FDA and CLIA-Waiver Commercialization Strategy
TABLE 232: U.S. Handheld Point-of-Care Testing Devices Market: Product Positioning and Assay Menu Expansion Guidance
TABLE 233: U.S. Handheld Point-of-Care Testing Devices Market: Installed-Base Expansion and Regional Commercial Prioritization
TABLE 234: U.S. Handheld Point-of-Care Testing Devices Market: Scope Limitation
TABLE 235: U.S. Handheld Point-of-Care Testing Devices Market: Market Definition and Product Inclusion Limitation
TABLE 236: U.S. Handheld Point-of-Care Testing Devices Market: Data Use Limitation
TABLE 237: U.S. Handheld Point-of-Care Testing Devices Market: Market Sizing Limitation
TABLE 238: U.S. Handheld Point-of-Care Testing Devices Market: Forecasting Limitation
TABLE 239: U.S. Handheld Point-of-Care Testing Devices Market: State-Level Estimation Limitation
TABLE 240: U.S. Handheld Point-of-Care Testing Devices Market: Regulatory and Reimbursement Information Limitation
TABLE 241: U.S. Handheld Point-of-Care Testing Devices Market: Legal Disclaimer
TABLE 242: U.S. Handheld Point-of-Care Testing Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Handheld Point-of-Care Testing Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Handheld Point-of-Care Testing Devices Market Ecosystem
FIGURE 4: Stakeholder Ecosystem Analysis
FIGURE 5: Value Chain Analysis
FIGURE 6: Supply Chain Analysis
FIGURE 7: PESTEL Analysis
FIGURE 8: Porter’s Five Forces Analysis
FIGURE 9: Market Attractiveness Analysis
FIGURE 10: Market Dynamics
FIGURE 11: Innovation & Patent Landscape, 2021–2025
FIGURE 12: Clinical Workflow Economics Framework
FIGURE 13: Time-to-Result and Clinical Decision Impact Framework
FIGURE 14: Hospital and Health System POC Procurement Decision Framework
FIGURE 15: U.S. Handheld Point-of-Care Testing Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 16: U.S. Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 17: U.S. Handheld Point-of-Care Testing Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 18: U.S. Handheld Point-of-Care Testing Devices Market Growth Opportunity Map, 2026–2035
FIGURE 19: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 20: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Handheld Blood Glucose and Metabolic Meters Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 22: Handheld Blood Gas, Electrolyte and Lactate Analyzers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 23: Handheld Coagulation and INR Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 24: Cardiac Biomarker and Critical-Care Handheld Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 25: Portable Infectious-Disease Readers and Molecular POC Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 26: Handheld Hemoglobin and Hematology Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 27: Product Type Growth Opportunity Matrix, 2026–2035
FIGURE 28: Clinical Test Category Market Share Analysis, 2025 & 2035
FIGURE 29: Clinical Test Category Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Glucose, HbA1c and Ketone Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 31: Blood Gas, Electrolyte and Lactate Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 32: Coagulation Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 33: Cardiac Biomarker Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 34: Infectious-Disease Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 35: Clinical Test Category Growth Opportunity Matrix, 2026–2035
FIGURE 36: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 37: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Hospitals and Health Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 39: Physician Offices and Primary Care Practices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 40: Urgent Care, Retail Clinics and Pharmacies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 41: Home Healthcare and Patient Self-Testing Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 42: EMS, Rural and Mobile Care Settings Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 43: Technology Segment Market Share Analysis, 2025 & 2035
FIGURE 44: Technology Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Electrochemical Biosensor Technology Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 46: Immunoassay and Fluorescence Reader Technology Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 47: Molecular and Nucleic-Acid Amplification Technology Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 48: Microfluidic and Lab-on-Chip Technology Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 49: Digitally Connected Multiparameter Platforms Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 50: U.S. Handheld POC Testing Procurement and Commercial Access Pathway
FIGURE 51: Installed-Base and Recurring Cartridge Revenue Model
FIGURE 52: Instrument Placement, Reagent Rental and Cost-per-Test Commercial Models
FIGURE 53: CLIA Waiver and Reimbursement Commercial Access Framework
FIGURE 54: IDN, GPO and Distributor Procurement Ecosystem
FIGURE 55: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 56: Regional Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: Regional POC Testing Infrastructure and CLIA-Waived Site Opportunity Map
FIGURE 58: West Region U.S. Handheld Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 59: West Region Market Share Analysis by State, 2025
FIGURE 60: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: California Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 62: Washington Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 63: Arizona Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 64: Colorado Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 65: Oregon Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 66: Utah Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 67: Nevada Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 68: New Mexico Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 69: Idaho Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 70: Montana Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 71: Wyoming Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 72: Alaska Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 73: Hawaii Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 74: Northeast Region U.S. Handheld Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 75: Northeast Region Market Share Analysis by State, 2025
FIGURE 76: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: New York Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 78: Massachusetts Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 79: New Jersey Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 80: Pennsylvania Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 81: Connecticut Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 82: Maine Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 83: Vermont Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 84: New Hampshire Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 85: Rhode Island Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 86: Delaware Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 87: South Region U.S. Handheld Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 88: South Region Market Share Analysis by State, 2025
FIGURE 89: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Texas Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 91: Florida Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 92: Georgia Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 93: North Carolina Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 94: Tennessee Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 95: South Carolina Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 96: Alabama Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 97: Mississippi Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 98: Louisiana Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 99: Arkansas Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 100: Kentucky Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 101: Oklahoma Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 102: Virginia Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 103: Maryland Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 104: West Virginia Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 105: Midwest Region U.S. Handheld Point-of-Care Testing Devices Market Share and Leading Players, 2025
FIGURE 106: Midwest Region Market Share Analysis by State, 2025
FIGURE 107: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Illinois Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 109: Ohio Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 110: Michigan Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 111: Minnesota Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 112: Indiana Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 113: Wisconsin Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 114: Missouri Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 115: Iowa Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 116: Kansas Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 117: Nebraska Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 118: North Dakota Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 119: South Dakota Handheld Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 120: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 121: Company Positioning Matrix
FIGURE 122: Key Player Product and Assay Portfolio Benchmarking
FIGURE 123: Key Player CLIA-Waived Portfolio and Connectivity Benchmarking
FIGURE 124: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 125: Handheld Point-of-Care Testing Innovation Roadmap
FIGURE 126: High-Sensitivity Cardiac Biomarker Testing Adoption Roadmap
FIGURE 127: Molecular Point-of-Care Diagnostics Growth Roadmap
FIGURE 128: Microfluidic and Lab-on-Chip Technology Opportunity Map
FIGURE 129: Connected and Decentralized POC Testing Growth Roadmap
FIGURE 130: Future of CLIA-Waived Testing Framework
FIGURE 131: Central Laboratory vs. Point-of-Care Testing Evolution
FIGURE 132: Future Market Scenario Analysis, 2026–2035
FIGURE 133: Disruptive Technologies Impact Matrix
FIGURE 134: Emerging Business Models Matrix
FIGURE 135: White-Space and Assay Expansion Opportunity Matrix
FIGURE 136: Investment Prioritization Matrix
FIGURE 137: Strategic Growth Roadmap for U.S. Handheld POC Testing Device Companies
FIGURE 138: Go-to-Market and Commercial Access Strategy Framework
FIGURE 139: FDA and CLIA-Waiver Commercialization Framework
FIGURE 140: Product Positioning and Assay Menu Expansion Framework
FIGURE 141: Installed-Base and Regional Commercial Expansion Roadmap
FIGURE 142: Report Scope, Market Boundary and Disclaimer Framework